Search｜Photos & Images & Videos｜KYODO NEWS IMAGES INC

Taiwan: Typhoon Danas Batters Southern Region, Leaving Widespread Damage 3

Typhoon Danas made landfall near Chiayi's Budai Township around 11:40 p.m. on Sunday, July 6, bringing gusty winds and heavy rainfall to the southern region. Typhoon Danas weakened to a tropical storm after its eye departed Taiwan early Monday.

E

Rekanemab NHI drug price listing Eisai press conference

Rekanemab NHI drug price listing Eisai press conference. Haruo Naito, Representative Executive Officer and CEO of Eisai Co.=Date:December 13, 2023, Place:Tokyo

E

Rekanemab NHI drug price listing Eisai press conference

Rekanemab NHI drug price listing Eisai press conference. Haruo Naito, Representative Executive Officer and CEO of Eisai Co.=Date:December 13, 2023, Place:Tokyo

E

Rekanemab NHI drug price listing Eisai press conference

Rekanemab NHI drug price listing Eisai press conference. Haruo Naito, Representative Executive Officer and CEO of Eisai Co.=Date:December 13, 2023, Place:Tokyo

E

Anti-Alzheimer's drug lecanemab

Haruo Naito, CEO of Japanese pharmaceutical company Eisai Co., attends a press conference in Tokyo on Dec. 13, 2023, as the company's anti-Alzheimer's drug lecanemab is set to be launched on Dec. 20, following a health ministry advisory body's approval of its coverage by the Japanese public insurance scheme.

E

Anti-Alzheimer's drug lecanemab

Haruo Naito, CEO of Japanese pharmaceutical company Eisai Co., attends a press conference in Tokyo on Dec. 13, 2023, as the company's anti-Alzheimer's drug lecanemab is set to be launched on Dec. 20, following a health ministry advisory body's approval of its coverage by the Japanese public insurance scheme.

E

Eisai CEO Naito

Haruo Naito, CEO of Japanese pharmaceutical company Eisai Co., speaks during a press conference in Tokyo on July 7, 2023, after the U.S. Food and Drug Administration granted full approval for Eisai and Biogen Inc.'s anti-Alzheimer's drug lecanemab.

E

Eisai CEO Naito

Haruo Naito, CEO of Japanese pharmaceutical company Eisai Co., speaks during a press conference in Tokyo on July 7, 2023, after the U.S. Food and Drug Administration granted full approval for Eisai and Biogen Inc.'s anti-Alzheimer's drug lecanemab.

E

Eisai CEO Naito

Haruo Naito, CEO of Japanese pharmaceutical company Eisai Co., speaks during a press conference in Tokyo on July 7, 2023, after the U.S. Food and Drug Administration granted full approval for Eisai and Biogen Inc.'s anti-Alzheimer's drug lecanemab.

E

Eisai CEO Naito

Haruo Naito, CEO of Japanese pharmaceutical company Eisai Co., speaks during a press conference in Tokyo on July 7, 2023, after the U.S. Food and Drug Administration granted full approval for Eisai and Biogen Inc.'s anti-Alzheimer's drug lecanemab.

E

U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.

E

U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.

E

U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.